Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients

被引:0
|
作者
Wang, Zhenhua [1 ,2 ]
Wu, Shuming [1 ,2 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Div Gastroenterol & Hepatol,Shanghai Inst Digest, Shanghai 200001, Peoples R China
[2] Shanghai Jiao Tong Univ, Key Lab Gastroenterol & Hepatol, Minist Hlth, Shanghai 200001, Peoples R China
关键词
doxycycline; Helicobacter pylori; quadruple therapy; rescue therapy; TRIPLE THERAPY; GASTRIC-CANCER; INFECTION; RESISTANCE; CLARITHROMYCIN; METRONIDAZOLE; 2ND-LINE; IMPACT; LEVOFLOXACIN; LANSOPRAZOLE;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction This study aimed to compare the efficacy and safety of quadruple therapy containing doxycycline and routine quadruple therapy for Helicobacter (H.) pylori rescue eradication in patients who had failed the one-week triple therapy. Methods Patients who failed the first-line eradication therapy were allocated into two groups. Group A patients (n = 43) were administered esomeprazole 20 mg, bismuth potassium citrate 220 mg, amoxicillin 1 g and doxycycline 100 mg, all bid for ten days, while Group B patients (n = 42) were administered esomeprazole 20 mg bid, bismuth potassium citrate 220 mg bid, metronidazole 400 mg bid and tetracycline 750 mg q.6h, for ten days. The results of H. pylori eradication were assessed with 13C urea breath test four weeks after the therapy, and the side effects were recorded. Results A total of 85 patients (average age 46.9 years) were enrolled in the study. Successful eradication rate for H. pylori was 72.5% in Group A and 64.1% in Group B, with no significant difference between the two groups. 11.6% (5/43) of patients from group A and 31.0% (13/42) from group B reported at least one adverse event. The adverse events of all 18 patients disappeared after the therapy ceased. Conclusion Quadruple therapy containing doxycycline is as effective as routine quadruple therapy for H. pylori rescue eradication. The regimen is well tolerated by most patients and causes fewer adverse events than routine quadruple therapy. Hence, it may be recommended as a suitable alternative H. pylori rescue regimen in China.
引用
收藏
页码:273 / 276
页数:4
相关论文
共 50 条
  • [21] An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy
    Moyle, G
    Higgs, C
    Teague, A
    Mandalia, S
    Nelson, M
    Johnson, M
    Fisher, M
    Gazzard, B
    ANTIVIRAL THERAPY, 2006, 11 (01) : 73 - 78
  • [22] Efficacy analysis of empirical bismuth quadruple therapy, high-dose dual therapy, and resistance gene-based triple therapy as a first-line Helicobacter pylori eradication regimen - An open-label, randomized trial
    Jiang, Xin
    Deng, Bin
    Gao, Xuefeng
    Zhang, Yun
    Li, Guangyao
    Li, Guiqing
    She, Qiang
    Ding, Yanbing
    OPEN MEDICINE, 2023, 18 (01):
  • [23] Helicobacter pylori Eradication with Ecabet Sodium, Omeprazole, Amoxicillin, and Clarithromycin Versus Bismuth, Omeprazole, Amoxicillin, and Clarithromycin Quadruple Therapy: A Randomized, Open-Label, Phase IV Trial
    Liang, Jie
    Li, Jun
    Han, Ying
    Xia, Jielai
    Yang, Yunsheng
    Li, Wen
    Zhang, Shutian
    Wu, Yongdong
    Yuan, Yaozong
    Li, Zhaoshen
    Du, Yiqi
    Chen, Minhu
    Chen, Baili
    Jiang, Bo
    Bai, Yang
    Wen, Qinsheng
    Wu, Kaichun
    Fan, Daiming
    HELICOBACTER, 2012, 17 (06) : 458 - 465
  • [24] Bismuth quadruple regimen with tetracycline or doxycycline versus Pylera® as third-line rescue therapy for H. pylori infection: A prospective multicenter analysis of the European Registry on Helicobacter pylori Management (Hp-EuReg)
    Nyssen, O. P.
    Perez-Aisa, A.
    Rodrigo-Saez, L.
    Castro-Fernandez, M.
    Mata Romero, P.
    Ortuno, J.
    Barrio, J.
    Huguet, J.
    Modollel, I.
    Alcaide, N.
    Lucendo, A.
    Calvet, X.
    Perona, M.
    Gomez, B.
    Rodriguez, B. Gomez
    Varela, P.
    Jimenez-Moreno, M.
    Dominguez-Cajal, M.
    Pozzati, L.
    Burgos, D.
    Bujanda, L.
    Hinojosa, J.
    Molina-Infante, J.
    Di Maira, T.
    Ferrer, L.
    Fernandez-Salazar, L.
    Figuerola, A.
    Tito, L.
    de la Coba, C.
    Gomez-Camarero, J.
    Fernandez, N.
    Caldas, M.
    Garre, A.
    Resina, E.
    Espada, M.
    Puig, I.
    Megraud, F.
    O'Morain, C.
    Gisbert, J. P.
    HELICOBACTER, 2020, 25 : 24 - 25
  • [25] Hybrid therapy as first-line regimen for Helicobacter pylori eradication in a high clarithromycin resistance area: a prospective open-label trial
    Georgopoulos, Sotirios D.
    Papastergiou, Vasilios
    Martinez-Gonzalez, Beatriz
    Xirouchakis, Elias
    Familias, Ioannis
    Sgouras, Dionysis
    Mentis, Andreas
    Karatapanis, Stylianos
    ANNALS OF GASTROENTEROLOGY, 2018, 31 (02): : 205 - 210
  • [26] Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial
    Liou, Jyh-Ming
    Jiang, Xiao-Tao
    Chen, Chieh-Chang
    Luo, Jiing-Chyuan
    Bair, Ming-Jong
    Chen, Po-Yueh
    Chou, Chu-Kuang
    Fang, Yu-Jen
    Chen, Mei-Jyh
    Chen, Chien-Chuan
    Lee, Ji-Yuh
    Yang, Tsung-Hua
    Yu, Chien-Chun
    Kuo, Chia-Chi
    Chiu, Min-Chin
    Chen, Chi-Yi
    Shun, Chia-Tung
    Hu, Wen-Hao
    Tsai, Min-Horn
    Hsu, Yao-Chun
    Tseng, Cheng-Hao
    Chang, Chi-Yang
    Lin, Jaw-Town
    El-Omar, Emad M.
    Wu, Ming-Shiang
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (03): : 228 - 241
  • [27] Third-line levofloxacin-based rescue regimen in patients with two Helicobacter pylori eradication failures:: A Spanish multicenter study
    Gisbert, J. P.
    HELICOBACTER, 2007, 12 (04) : 427 - 427
  • [28] Optimal duration of concomitant nonbismuth quadruple therapy as first-line therapy for Helicobacter pylori: a prospective, open-label, comparative study
    Kapizioni, Christina
    Koutoufaris, Georgios
    Ntouli, Vasiliki
    Makris, Konstantinos
    Milioni, Konstantia
    Kourkoulis, Panagiotis
    Giannelis, Panagiotis
    Mellos, Aristotelis
    Michalopoulos, Georgios
    Vrakas, Spyridon
    Xourgias, Vasileios
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 31 (10) : 1206 - 1210
  • [29] A New Four-day Regimen with Dexlansoprazole, Moxifloxacin, Amoxicillin, Nitazoxanide, and Doxycycline (DeMAND) in Helicobacter Pylori Therapy: An Open-label Randomized Clinical Trial
    Basu, P. Patrick
    Krishnaswamy, Nithya
    Korapati, Ramya
    Tammishetti, Swapna
    Shah, Niraj James
    Pacana, Tommy
    Hampole, Hemanth
    Tang, Chris
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S81 - S81
  • [30] Modified quadruple therapy versus bismuth-containing quadruple therapy in first-line treatment of Helicobacter pylori infection in Korea; rationale and design of an open-label, multicenter, randomized controlled trial
    Lim, Hyun
    Bang, Chang Seok
    Shin, Woon Geon
    Choi, Jae Ho
    Soh, Jae Seung
    Kang, Ho Suk
    Yang, Young Joo
    Hong, Ji Taek
    Shin, Suk Pyo
    Suk, Ki Tae
    Lee, Jae Jun
    Baik, Gwang Ho
    Kim, Dong Joon
    MEDICINE, 2018, 97 (46)